⌕
AbCellera Biologics · ABCL · Nasdaq
Tenet 49 · Mixed
Compare
$11.03−0.81%At closeTenet 49 · Mixed
$11.03−0.09 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AbCellera Biologics (ABCL) Institutional Ownership

13F filers reported holding 42.5% of AbCellera Biologics (ABCL) shares as of Sep 30, 2026, across 164 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
42.5%
Sep 30, 2026
13F filers
164
quarter ended Sep 30, 2026
13F value
$2.0B
139.0M shares
Quarter's fund flow
Mild accumulation
45 new · 31 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (45 new · 47 increased · 56 reduced · 31 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 164 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 13, 2026Booth AndrewChief Financial OfficerAcquired · Option exercise50,000Common Shares$0.32↗
Nov 13, 2026Booth AndrewChief Financial OfficerDisposed · Gift50,000Common Shares—↗
Nov 13, 2026Booth AndrewChief Financial OfficerDisposed · Option exercise50,000Share option (right to buy)—↗
Nov 13, 2026Thermopylae Holdings Ltd.10% ownerDisposed · Gift125,000Common Shares—↗
Nov 13, 2026Booth AndrewChief Financial OfficerAcquired · Open-market buy8,600Common Shares$11.33↗
Nov 12, 2026Thermopylae Holdings Ltd.10% ownerAcquired · Open-market buy60,565Common Shares$11.54↗
Aug 24, 2026Hayden Michael RdirectorAcquired · Open-market buy53,613Common Shares$10.64↗
Aug 18, 2026Montalbano John S.directorAcquired · Open-market buy10,000Common Shares$11.03↗
Aug 14, 2026Booth AndrewChief Financial OfficerAcquired · Open-market buy37,200Common Shares$10.32↗
Aug 12, 2026Hayden Michael RdirectorAcquired · Open-market buy46,387Common Shares$10.37↗
Aug 11, 2026Hayden Michael RdirectorDisposed · Gift50,000Common Shares—↗
Jul 1, 2026Seely LynndirectorAcquired · Grant / award152,207Share option (right to buy)—↗
Jul 1, 2026Sandor VictordirectorAcquired · Grant / award152,207Share option (right to buy)—↗
Jun 11, 2026Montalbano John S.directorAcquired · Grant / award111,701Share option (right to buy)—↗
Jun 11, 2026Quake StephendirectorAcquired · Grant / award111,701Share option (right to buy)—↗
Jun 11, 2026Hayden Michael RdirectorAcquired · Grant / award111,701Share option (right to buy)—↗
Jun 3, 2026Booth AndrewChief Financial OfficerAcquired · Option exercise250,000Common Shares$0.19↗
Jun 3, 2026Booth AndrewChief Financial OfficerDisposed · Option exercise250,000Share option (right to buy)—↗
May 14, 2026Montalbano John S.directorAcquired · Open-market buy20,000Common Shares$4.77↗
Feb 27, 2026Thermopylae Holdings Ltd.10% ownerAcquired · Open-market buy38,000Common Shares$3.44↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of AbCellera Biologics do institutions hold?

13F filers reported holding 42.5% of AbCellera Biologics' shares as of Sep 30, 2026, across 164 filers.

How many 13F filers hold AbCellera Biologics?

AbCellera Biologics was held by 164 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.